HC Wainwright Reiterates Buy Rating on Gain Therapeutics
HC Wainwright maintains its bullish stance on Gain Therapeutics with an $8 price target, a 294.09% upside from the current price.
Key Points
- HC Wainwright reiterated its Buy rating on Gain Therapeutics, setting a price target of $8 on July 1, 2026.
- HC Wainwright's $8 price target implies 294.09% upside from Gain Therapeutics, Inc.'s ($GANX) current $2.03 share price.
- Gain Therapeutics traded at $2.03 on NasdaqGM with a market cap of approximately $86.6 million.
- Multiple insiders purchased shares, and institutional activity showed mixed changes in holdings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright has reiterated its Buy rating on Gain Therapeutics, Inc. (NasdaqGM: GANX), maintaining a price target of $8. This reaffirmation came on July 1, 2026, with analyst Raghuram Selvaraju expressing continued confidence in the company's prospects.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Gain Therapeutics
Marshall Wace, LLP increased its holdings by 107,495 shares, bringing its total to 1,769,788 shares valued at about $3.43 million. Meanwhile, Potomac Capital Management, Inc. slightly reduced its position by 1,400 shares, ending with 1,008,600 shares worth approximately $1.96 million. Jones Financial Companies LLLP cut its stake by 70,598 shares, leaving it with 631,615 shares valued at $1.16 million. On the other hand, Geode Capital Management, LLC added 49,400 shares, totaling 447,342 shares valued at $868,527. Cambridge Investment Research Advisors, Inc. and DME Capital Management, LP maintained their positions.
Gain Therapeutics, Inc. Stock Up 14.7%
Shares of Gain Therapeutics traded near $2.03 on Wednesday. The company has a market cap of roughly $86.6 million. It operates in the biotechnology sector and has a beta of 0.164, suggesting lower volatility compared to the broader market. The stock's 52-week range spans from $1.41 to $4.34, with a 50-day moving average of $1.83 and a 200-day moving average of $2.20. The company holds a strong liquidity position, with a current ratio of 4.69 and a quick ratio of 4.51, although it has a debt-to-equity ratio of 4.8.
$GANX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Gain Therapeutics, Inc.
On March 24, 2026, CEO Gene Mack purchased 200,000 shares, while Gianluca Fuggetta acquired 50,000 shares. These transactions were not under a prearranged trading plan. Earlier, on June 24, 2025, several insiders, including Jeffrey Scott Riley, Eric Richman, Claude Nicaise, and Khalid Islam, each bought 15,000 shares.
Analysts Set New Price Targets
On July 1, 2026, HC Wainwright & Co. reiterated its Buy rating on Gain Therapeutics, setting an $8 price target. The consensus among analysts is a Buy rating, with a mean target price of $7.20, based on five analyst opinions.
About Gain Therapeutics
Gain Therapeutics, Inc. is a biotechnology company based in Bethesda, Maryland. It focuses on developing small molecule therapeutics to treat various diseases, including Parkinson's and Alzheimer's. The company's Magellan drug discovery platform identifies novel allosteric binding sites, aiming to modulate protein function to address disease causes. Founded in 2017, Gain Therapeutics is led by CEO Gene Mack and employs about 20 people.
Bottom Line
HC Wainwright's reaffirmation of its Buy rating reflects ongoing confidence in Gain Therapeutics' potential, despite the stock's current trading price. Investors and analysts closely watch the company's innovative approach in biotechnology. Insider purchases and varied institutional activity highlight continued interest in the company's future prospects.
Get Gain Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $GANX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.